A Clinical study to which Anti-emetic effect of change of 5-HT3RA is evaluated by using MAT in MEC for gastrointestinal cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2013
At a glance
- Drugs Palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 04 Oct 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 04 Sep 2012 New trial record